Advertisement

Topics

Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients with Dementia with Lewy Bodies (DLB)

01:35 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Amendment of global R&D and commercialisation partnership between Heptares and Allergan designed to expand clinical development of HTL0018318 in major dementia indication HTL0018318 is a novel muscarinic M1 receptor...

Other Sources for this Article

Sosei Group Corporation
Chris Cargill, +44 (0)7912 892 199
Head of Investor Relations and Corporate Communications
ccargill@sosei.com
or
Harumi Banse, +81-(0)3-5210-3399
Investor Relations and Corporate Communications (Japan)
hbanse@sosei.com

NEXT ARTICLE

More From BioPortfolio on "Sosei to Advance Clinical Development in Japan of HTL0018318 in Patients with Dementia with Lewy Bodies (DLB)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Dementia
Dementia describes a range of symptoms of cognitive decline. For example memory loss, problems with reasoning and communication skills, and a reduction in a person's abilities and skills in carrying out daily activities. There are about 820,000 peo...